BCDA Q3'26 Earnings: EPS estimate is (0.13) USD

BioCardia (BCDA) will report Q3'26 earnings on November 12. Analysts expect $0 revenue and a loss of $0.13 per share. Results will be released after market close.

Original reporting
Published Nov 11, 2026, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 12:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
BCDA Q3'26 Earnings: EPS estimate is (0.13) USD — source image
Decision brief

The 30-second read

$BCDABearishLow
01

Why it matters

The negative EPS estimate may set expectations for a price decline unless the actual results exceed the forecast.

02

Market read

The preview influences short‑term trading decisions for BCDA and may affect sentiment in the broader biotech space.

03

What to watch

Potential upcoming clinical data or partnership announcements not mentioned could offset the loss forecast.

Relevance 4/10Novelty 3/10Timing: pre‑market today

Background

BioCardia is a small‑cap biotech that reports quarterly results on a scheduled basis.

Company-level read

Ticker impact

$BCDABearishMedium confidence
Context

Article provides the Q3'26 earnings estimate (EPS (0.13) USD) ahead of the November 12 release.

Expected impact

potential pressure if actual earnings miss the -0.13 USD estimate

Evidence & confidence

The negative EPS estimate signals a loss, which could lead to sell‑off unless the actual results beat expectations.

Market effects

Biotech sector may see slight bearish sentiment as a peer reports a loss forecast.

US small‑cap biotech investors may adjust positions ahead of the release.

Limited to investors tracking BioCardia and comparable biotech earnings.

Counterpoint

If the company surprises to the upside, the stock could rally sharply despite the negative estimate.

Key entities

  • BioCardia, Inc.

    US‑listed biotech (NASDAQ: BCDA) reporting Q3'26 earnings.

Related articles

$BCDAMed

BioCardia Inc (BCDA) (Q3 2026) Earnings Call Highlights: Japan Shonin Submission Advances

BioCardia Inc (BCDA) reported Q3 2026 earnings, highlighting progress in Japan's Shonin submission for CardiAMP Cell Therapy, expected within months. CEO Peter Altman discussed partnerships, regulatory pathways, and clinical trial updates. The company reported $1.7M in net cash used in operations, with $2.2M in cash reserves. Key catalysts include FDA feedback on the Helix catheter system and potential gene therapy partnerships.

$BCDAMedAI 8/10

BioCardia’s CardiAMP Completes Japan Pre-Market Consultation, First Cardiac Cell Therapy to Do So

BioCardia (BCDA) completed Japan's PMDA consultation for its CardiAMP Cell Therapy System, positioning it for a marketing approval application. The therapy, which uses a patient's own bone marrow cells, aims to treat heart damage. BioCardia targets a formal submission by late 2026 and commercial revenue by 2028. The company's Phase 3 trial showed significant improvements in a subgroup of patients with elevated NTproBNP levels, which PMDA has reviewed positively.

$BCDAMed

BioCardia Completes Clinical Consultation Process with Japan's PMDA for CardiAMP Cell Therapy System, Advancing Toward Submission of Marketing Approval…

BioCardia, Inc. (BCDA) filed an SEC Form 8-K — Other Events. Exhibit 99.1 BioCardia Completes Clinical Consultation Process with Japan's PMDA for CardiAMP Cell Therapy System, Advancing Toward Submission of Marketing Approval Application SUNNYVALE, Calif., November 6, 2026 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. (NASDAQ: BCDA) , a global le

$BCDAMedAI 8/10

BioCardia Advances Helix Catheter Toward FDA Marketing Clearance

BioCardia (BCDA) submitted a revised De Novo pre-submission package to the FDA for its Helix catheter, following feedback. The FDA accepted the submission and expects review, feedback, and a meeting in Q4 2026. The catheter is designed for delivering therapeutic agents to heart muscle and has clinical safety data from 15 trials. FDA clearance could expand partnership opportunities for BCDA.